Drug Profile
Research programme: Parkinson's disease gene therapy - RheoGene
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator RheoGene; University of Pittsburgh Medical Center
- Class Small molecules
- Mechanism of Action Genetic transcription inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 02 Nov 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the Parkinson's disease and Movement disorders pharmacodynamics section
- 12 Jan 2006 Preclinical trials in Parkinson's disease in USA (unspecified route)